A Single-Arm, Open-Label, Phase 1/2 Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of ALLO-501A, an Anti-CD19 Allogeneic CAR T Cell Therapy, and ALLO-647, an Anti-CD52 Monoclonal Antibody, in Subjects with Relapsed/Refractory Large B-Cell Lymphoma (LBCL)
Latest Information Update: 20 Feb 2025
At a glance
- Drugs Cemacabtagene ansegedleucel (Primary) ; ALLO 647; Cyclophosphamide; Fludarabine
- Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms ALPHA2
- Sponsors Allogene Therapeutics
Most Recent Events
- 13 Feb 2025 Results presented in the Allogene Therapeutics Media Release.
- 13 Feb 2025 According to an Allogene Therapeutics media release, durable response data from Phase 1 ALPHA and ALPHA2 clinical studies of cemacabtagene ansegedleucel in relapsed/refractory large B-cell lymphoma published as a Rapid Communication in the Journal of Clinical Oncology.
- 24 Jan 2025 Planned primary completion date changed from 1 Jan 2025 to 1 Aug 2025.